" On November 19, 2012, judges of the Texas State Office of Administrative Hearings dismissed the Texas Medical Board’s pending case against Dr. Burzynski. The investigation started by the board in 2008 involved Dr. Burzynski’s novel off-label use of combination gene targeted therapy. Early on, two medical
board informal settlement panels found that the use of these combination drugs on the advanced cancer patients involved was within the standard of care. However, the Texas Medical Board refused to drop the case and instead filed a formal complaint against Dr. Burzynski alleging the same standard of care violations previously rejected by the board settlement panels."
This ruling is wonderful news for healthcare in the United States. To learn how the AMA and FDA collude with the pharmacology industry to ignore cancer cures and prevention and instead promote "managing cancer," please start with these links: Burzynski: The Movie, Cut, Poison, Burn , and The Beautiful Truth .